Runt-related transcription factor-2 (RUNX2) is an integral player in osteogenesis and is highly expressed in osteosarcoma.
First-pass extracted concept
RUNX2
Candidate: concept label1 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
Runt-related transcription factor-2
Evidence Snippets
Supporting Sources
Linked Claims
RUNX2 is highly expressed in osteosarcoma and aberrant RUNX2 expression is described as a key factor in osteosarcoma oncogenesis.
Quoted textsource-backed
RUNX2 is an integral player in osteogenesis and is highly expressed in osteosarcoma. Emerging evidence suggests that aberrant RUNX2 expression is a key factor in osteosarcoma oncogenesis.
RUNX2 and HIF-1α are described as supporting each other or acting synergistically in osteosarcoma progression and therapy resistance.
Quoted textsource-backed
the intricate network between RUNX2 and HIF-1α, which support each other or may work synergistically to develop resistance to therapy and osteosarcoma progression
RUNX2 and HIF-1α are implicated in tumour microenvironment alteration that promotes angiogenesis, metastasis, and therapy resistance in osteosarcoma.
Quoted textsource-backed
this review focuses on the role of RUNX2 and HIF-1α in the alteration of the tumour microenvironment, which further promotes angiogenesis, metastasis, and resistance to therapy in osteosarcoma.
Osteosarcoma patients overexpressing RUNX2 are more likely to have high tumour grade, metastasis, and lower overall or progression-free survival.
Quoted textsource-backed
Patients with advanced stages of osteosarcoma overexpressing RUNX2 are more likely to have high tumour grades, metastasis, and lower overall or progression-free survival rates.
RUNX2 is considered a potential targeted therapy candidate in osteosarcoma.
Quoted textsource-backed
Thus, RUNX2 is considered a potential candidate for targeted therapy of osteosarcoma.